HOTH News and Press, Hoth Therapeutics Inc. From 12/31/20

Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment PR Newswire NEW YORK , Dec. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP ...

Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients PR Newswire NEW YORK , Dec. 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company,&#x...

Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model PR Newswire NEW YORK , Dec. 21, 2020 /PRNewswire/ -- Hoth (NASDAQ: HOTH) has a partnership agreement with Zylö Therapeutics Inc....

Hoth Therapeutics, Inc. (HOTH) has been granted the approval to advance its Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia.The approval by the Human Research Ethics Committee in Australia is a “critical milestone towards i...

Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans NEW YORK , Dec. 10, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a biopharmaceutical company, today announce...

Immutep (IMMP) +132% after breast cancer trial shows promising survival data.Greenwich LifeSciences (GLSI) +57%.UTStarcom Holdings (UTSI) +50%.Panbela Therapeutics (PBLA) +46%.Leju Holdings (LEJU) +38%.SELLAS Life Sciences (SLS) +36%.ClearOne (CLRO) +35% to expand its footprint in M...

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it will participate in the 2020 Fall TechConnect Virtual Innovation Conferences' Virtual Defense TechConnect Innovation Summit . The conference will be held November 17-19, 2020. ...

Hoth Therapeutics ([[HOTH]] +4.2%) has announced positive, proof-of-concept preclinical data for its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus ((CLE)), a chronic autoimmune skin disease.The study conducted by Jackson Laboratory in partnership with Zyl...

Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease The study was conducted by Jackson Laboratory in partnership with Zylö Therapeutic...

Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine Hoth Therapeutics expects key proof-of-concept data in Q4 2020 / Q1 2021 for its COVID-19 products it is currently developing PR Newswire NEW YORK, Nov. 2, ...